ASC Valuation in 2027: Multiples, What Buyers Pay For and How Margin Moves the Price
Why EBITDA margin, not revenue, decides whether your center prices at 5x or 17x EBITDA, and what buyers check before they offer either number.
ASC valuation in 2027: how EBITDA margin, ownership structure and case costing data decide whether your center prices at 5x or 17x.

The multiple is a symptom, not the price
ASC valuation in 2027 starts with a wide range: single-specialty centers trade near 5 to 8 times EBITDA, multi-specialty centers near 6 to 10 times, and multi-site platforms command 11 to 17 times (FOCUS Investment Bankers, April 2026). The spread looks like a market story. It is mostly a margin story.
A buyer is not pricing your revenue. A buyer is pricing the cash your center produces after supplies, labor, rent and everything else, then applying a multiple that reflects how confident they are that cash repeats. Two centers with identical revenue can sell for very different numbers if one runs at a 13% EBITDA margin and the other at 30%.
Why margin drives the multiple more than size does
The benchmark gap is large and well documented. Centers under $3 million in net revenue post an average EBITDA margin of 12.8%, while centers over $9 million post 37.3% (Surgical Information Systems, 2019). Well-run centers of any size land in the 20% to 30% range (ASC News, 2025). The industry-wide average across centers of every size and quality sits closer to 15.9% (IBISWorld, via Vertess, 2026).
That gap is almost entirely operational: block utilization, first case starts, turnover time, supply cost per case, staff hours per case, denial rate and days in AR. None of it is about revenue size. A buyer who sees a center with documented case costs and clean scheduling discipline is buying a margin they can underwrite with confidence. A buyer who sees a center that knows its margin once a year, from a tax return, prices in the uncertainty. That discount shows up in the multiple, not in a single line item.
What buyers actually diligence
Before a letter of intent gets priced, a buyer's diligence team asks for the same things your own board should already be asking for every quarter:
- Contribution margin by procedure, by surgeon and by payer, not just revenue by procedure.
- Block utilization and first-case on-time start rates by surgeon, trended over at least a year.
- Supply cost per case on the top 20 procedures, separated from implant cost.
- Denial rate and days in accounts receivable, with the aging detail behind both.
- Physician ownership structure and each owner's compliance with the federal safe harbor conditions, including meaningful case volume performed at the center.
- Payer contracts, including whether new procedures from the 2026 covered list carry a negotiated commercial rate or still price off a blanket Medicare multiple.
A center that can hand over this packet in an afternoon is a different diligence process than one that needs six weeks to reconstruct it. The time difference is itself a signal to the buyer about how the center is run day to day, separate from what the numbers on the page actually say.
Multiples by structure
| Structure | Typical EBITDA multiple |
|---|---|
| Single-specialty center | 5 to 8 times |
| Multi-specialty center | 6 to 10 times |
| Multi-site platform | 11 to 17 times |
The jump from single center to platform is not only about scale. A platform buyer is paying for the ability to apply one playbook, one supply contract and one case costing system across many rooms. A single center that already runs that way on its own, with documented contribution margin and schedule discipline, is closer to platform economics than its size suggests, and that shows up at the negotiating table even if it never shows up on a multiple table.
The quality reporting penalty and why it matters to a buyer
The CY 2026 Medicare rule ties a 2.6% payment update to meeting the ASC Quality Reporting Program requirements (CMS, November 2025). Centers that miss the reporting threshold lose 2.0 percentage points off the annual update (CMS). A buyer reviewing three years of financials notices immediately whether that swing has already happened. A missed quality submission is a cheap, visible way to lower your own number before anyone from the buy side has looked at a single invoice.
Ownership, management fees and the site neutrality tailwind
About 62% of ASC market revenue sits in physician-owned centers (Grand View Research, 2025). Hospital, corporate and joint venture structures hold the rest. Each structure prices differently. A management company commonly charges 4% to 7% of net revenue in addition to an equity stake (commonly reported, industry convention), a cost a buyer underwrites against the margin it is already paying for. A hospital joint venture trades a share of profit for referral stability and contracting weight, which can raise the price a health system is willing to pay even when the standalone center would not command it on the open market.
Medicare's direction adds a tailwind that buyers are already pricing in. The CY 2026 rule added 560 procedures to the ASC covered list, 271 of them freed from the inpatient only phase-out, with 35 ancillary services added alongside them (CMS, November 2025). Site neutral payment policy, which pays the same rate for the same service regardless of where it happens, continues to narrow the gap between hospital outpatient rates and ASC rates (MedPAC). Every procedure that moves from inpatient only to ASC-eligible is addressable volume a buyer can underwrite into next year's pro forma, provided the center can prove the contribution margin on that procedure before it adds the case.
Regulatory friction still varies by state. Thirty-five states plus the District of Columbia run some form of certificate of need program, though several exempt ASCs outright or apply a lighter review (AHPA and NCSL summaries, 2025). A buyer comparing two otherwise identical centers in a CON state and a non-CON state is pricing the second one as easier to expand, and that difference is part of the multiple too.
How to value your own center before a buyer does
How to value your ambulatory surgery center starts with the same discipline a buyer will apply, run on your own schedule instead of theirs. Pull trailing twelve months of cases by payer, procedure and surgeon. Calculate contribution margin using consumption, not the preference card: what was opened and used, not what was ordered. Rank procedures and surgeons by that number. The bottom of the list is where the operational fixes live, and those fixes are the same ones that raise the margin a buyer prices.
This ground is covered in more depth in our primer on ASC ownership and economics, and it matters whether you are planning to sell, bring in a hospital partner, or simply report a cleaner number to your own board. If a management company is part of the conversation, understand the fee structure and what it buys before the term sheet, not after; our comparison of ASC management companies covers what they typically charge and how to compare them. If your own staff cannot produce case costing, scheduling and payer data on short notice, that gap is worth closing before a consultant or a buyer finds it first; our guide to hiring a surgery center consultant covers what that engagement should cost and what to expect from it. Licensing and accreditation records matter too; a messy compliance file is its own kind of discount, as covered in our ASC compliance checklist for 2027.
For owners building or expanding rather than selling, the same case costing discipline belongs in the pro forma from day one; see our guide to opening an ASC in 2027 for the construction cost, timeline and licensing detail that every later valuation conversation depends on.
What to do this quarter
- Pull contribution margin by procedure, surgeon and payer for the trailing twelve months, using consumption data, not preference cards. This is the single document every buyer and every bank will ask for first.
- Calculate your own EBITDA margin and place it against the benchmark range for your revenue size (12.8% to 37.3%, Avanza). Know which side of that range you sit on before anyone else tells you.
- Confirm your ownership structure meets the federal safe harbor conditions for every physician investor, and document it in writing. A clean ownership file is diligence a buyer does not have to discount for.
Related reading
- How to Open an ASC in 2027
- What Is an Ambulatory Surgery Center (ASC)? Definition, Economics and Who Owns Them
- ASC Compliance Checklist 2027: Licensing, Medicare Conditions for Coverage and Life Safety
- ASC Management Companies: What They Do, What They Typically Charge and How to Compare Them
- The ASC resource hub: every Sigmatic guide on ambulatory surgery centers
Make your ASC more profitable
Sigmatic is a team of ASC consultants who use our own technology to manage surgery centers: better margins, better workflows, and a real-time view of cost per case and utilization that keeps the gains in place. If the numbers in this article look like your center, book a free 30-minute consultation and we will go through your own figures and show you where the margin is. Read the How to Open an ASC in 2027 guide, grab the free PDF, The 2027 ASC State of the Union: maximizing profit on razor-thin margins, from the form on this page, or email [email protected].
Free guide
The 2027 ASC State of the Union: Maximizing profit on razor-thin margins
16 pages of charts: the market, the 2026 reimbursement rules, the benchmarks that separate a 13 percent margin from a 37 percent one, a case costing method you can run this month and a 90-day plan.
Before you go
Want a more profitable ASC?
Book a free 30-minute consultation on your own numbers, or leave your email and we will send the 2027 guide first.
Make your ASC more profitable.
A free 30-minute consultation on your own numbers: where the margin is, what to fix first. No obligation.